echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New indications of Fosun Kate Akilunsai injection are planned to be included in breakthrough treatment products

    New indications of Fosun Kate Akilunsai injection are planned to be included in breakthrough treatment products

    • Last Update: 2021-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 9th, the CDE official website showed that Fosun Kate Akirensai injection is planned to be included in the list of breakthrough treatment products.


    On June 23, the State Food and Drug Administration has approved a new drug application for Akirensai injection, which is the first cell therapy product approved for marketing in China for the treatment of relapses after previous second-line or above systemic treatments Or refractory large B-cell lymphoma (r/r LBCL) adult patients, including diffuse large B-cell lymphoma (DLBCL) non-specific (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma and follicular lymphoma transformed DLBCL1


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.